Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDG-5506 biomarker response to exercise study in adults with Becker muscular dystrophy, McArdle disease, or limb-girdle muscular dystrophy
2022-500215-39-00Phase 2Completed
- Sponsor
- Edgewise Therapeutics
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Becker muscular dystrophy (BMD), glycogen storage disease type V (GSDV) and limb-girdle muscular dystrophy (LGMD) comparing EDG-5506 with Placebo (2 arms). Primary endpoints: Adverse events and serious adverse events and Change in serum creatine kinase at week 16. Started Dec 2022; status: completed.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)glycogen storage disease type V (GSDV)limb-girdle muscular dystrophy (LGMD)
Beyond the preview
Go deeper on 2022-500215-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500215-39-00.